$62.01 Million in Sales Expected for Inogen Inc (INGN) This Quarter
Equities research analysts expect Inogen Inc (NASDAQ:INGN) to post sales of $62.01 million for the current quarter, according to Zacks. Three analysts have issued estimates for Inogen’s earnings, with estimates ranging from $61.71 million to $62.20 million. Inogen reported sales of $50.85 million in the same quarter last year, which indicates a positive year over year growth rate of 21.9%. The business is expected to announce its next earnings results after the market closes on Tuesday, February 27th.
On average, analysts expect that Inogen will report full year sales of $62.01 million for the current year, with estimates ranging from $242.00 million to $247.80 million. For the next year, analysts forecast that the business will post sales of $297.74 million per share, with estimates ranging from $286.10 million to $304.27 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Inogen.
Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same quarter in the previous year, the firm posted $0.25 earnings per share. Inogen’s revenue was up 26.8% compared to the same quarter last year.
Inogen (INGN) opened at $119.37 on Thursday. Inogen has a 52-week low of $64.84 and a 52-week high of $130.05. The stock has a market cap of $2,456.02, a price-to-earnings ratio of 97.05, a P/E/G ratio of 3.99 and a beta of 1.02.
In other news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $112.35, for a total value of $280,875.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Byron Myers sold 35,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the completion of the sale, the executive vice president now directly owns 48,600 shares in the company, valued at approximately $5,675,022. The disclosure for this sale can be found here. Insiders sold a total of 113,651 shares of company stock worth $13,299,463 in the last three months. Insiders own 5.31% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Lenox Wealth Advisors Inc. acquired a new position in Inogen during the 4th quarter worth about $100,000. Steward Partners Investment Advisory LLC lifted its position in Inogen by 1,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after buying an additional 1,000 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Inogen by 6.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares in the last quarter. Simplex Trading LLC acquired a new position in Inogen during the 4th quarter worth about $153,000. Finally, LS Investment Advisors LLC lifted its position in Inogen by 138.6% during the 4th quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after buying an additional 880 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.